Developing an HIV vaccine

In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a v...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2017-03, Vol.355 (6330), p.1129-1130
Main Authors: Haynes, Barton F., Burton, Dennis R.
Format: Article
Language:English
Subjects:
AIDS Vaccines - immunology
Animals
Antibodies
Antiretroviral agents
Antiretroviral drugs
Clinical Trials as Topic
gag Gene Products, Human Immunodeficiency Virus - genetics
gag Gene Products, Human Immunodeficiency Virus - immunology
Genomes
Health problems
HIV
HIV Envelope Protein gp120 - genetics
HIV Envelope Protein gp120 - immunology
HIV Infections - prevention & control
HIV Infections - therapy
HIV Protease - genetics
HIV Protease - immunology
Human immunodeficiency virus
Humans
Immunogenicity, Vaccine
Infections
Lentivirus
Life cycle engineering
Mice
Neutralizing
PERSPECTIVES
Protein Multimerization
Retarding
Retroviridae
Sole
T-Lymphocytes, Cytotoxic - immunology
Vaccination
Vaccines
Vaccines, Synthetic - immunology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43
cites cdi_FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43
container_end_page 1130
container_issue 6330
container_start_page 1129
container_title Science (American Association for the Advancement of Science)
container_volume 355
creator Haynes, Barton F.
Burton, Dennis R.
description In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) "spike" that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?
doi_str_mv 10.1126/science.aan0662
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893901327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24918004</jstor_id><sourcerecordid>24918004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43</originalsourceid><addsrcrecordid>eNqN0U1Lw0AQBuBFFFurZ_GgFLx4STu7m2xnj1I_Wih4Ua9hM5lISprUbFPw3xttVPDU0xzmmYGZV4hzCSMplRl7yrkkHjlXgjHqQPQl2CiwCvSh6ANoEyBMop448X4J0PasPhY9hRoUStUXF3e85aJa5-Xb0JXD2fx1uHVEecmn4ihzheezrg7Ey8P983QWLJ4e59PbRUDaWBXIELNIhdJIMElGqCIbESHhBCOVhAmSZsoyTZxSahK2ihgRo9TJyDKFeiBudnvXdfXesN_Eq9wTF4UruWp8LNFqC1KryR4U0RplwOxBJ4hKgZUtvf5Hl1VTl-3N30oao9tHDsR4p6iuvK85i9d1vnL1Rywh_soi7rKIuyzaiatub5OsOP31P89vweUOLP2mqv_6oZUIEOpPcASMkw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878166300</pqid></control><display><type>article</type><title>Developing an HIV vaccine</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Science Online_科学在线</source><source>Alma/SFX Local Collection</source><creator>Haynes, Barton F. ; Burton, Dennis R.</creator><creatorcontrib>Haynes, Barton F. ; Burton, Dennis R.</creatorcontrib><description>In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) "spike" that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?</description><identifier>ISSN: 0036-8075</identifier><identifier>EISSN: 1095-9203</identifier><identifier>DOI: 10.1126/science.aan0662</identifier><identifier>PMID: 28302812</identifier><language>eng</language><publisher>United States: American Association for the Advancement of Science</publisher><subject>AIDS Vaccines - immunology ; Animals ; Antibodies ; Antiretroviral agents ; Antiretroviral drugs ; Clinical Trials as Topic ; gag Gene Products, Human Immunodeficiency Virus - genetics ; gag Gene Products, Human Immunodeficiency Virus - immunology ; Genomes ; Health problems ; HIV ; HIV Envelope Protein gp120 - genetics ; HIV Envelope Protein gp120 - immunology ; HIV Infections - prevention &amp; control ; HIV Infections - therapy ; HIV Protease - genetics ; HIV Protease - immunology ; Human immunodeficiency virus ; Humans ; Immunogenicity, Vaccine ; Infections ; Lentivirus ; Life cycle engineering ; Mice ; Neutralizing ; PERSPECTIVES ; Protein Multimerization ; Retarding ; Retroviridae ; Sole ; T-Lymphocytes, Cytotoxic - immunology ; Vaccination ; Vaccines ; Vaccines, Synthetic - immunology ; Viruses</subject><ispartof>Science (American Association for the Advancement of Science), 2017-03, Vol.355 (6330), p.1129-1130</ispartof><rights>Copyright © 2017 American Association for the Advancement of Science</rights><rights>Copyright © 2017, American Association for the Advancement of Science</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43</citedby><cites>FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24918004$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24918004$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,2884,2885,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28302812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haynes, Barton F.</creatorcontrib><creatorcontrib>Burton, Dennis R.</creatorcontrib><title>Developing an HIV vaccine</title><title>Science (American Association for the Advancement of Science)</title><addtitle>Science</addtitle><description>In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) "spike" that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?</description><subject>AIDS Vaccines - immunology</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Clinical Trials as Topic</subject><subject>gag Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>gag Gene Products, Human Immunodeficiency Virus - immunology</subject><subject>Genomes</subject><subject>Health problems</subject><subject>HIV</subject><subject>HIV Envelope Protein gp120 - genetics</subject><subject>HIV Envelope Protein gp120 - immunology</subject><subject>HIV Infections - prevention &amp; control</subject><subject>HIV Infections - therapy</subject><subject>HIV Protease - genetics</subject><subject>HIV Protease - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunogenicity, Vaccine</subject><subject>Infections</subject><subject>Lentivirus</subject><subject>Life cycle engineering</subject><subject>Mice</subject><subject>Neutralizing</subject><subject>PERSPECTIVES</subject><subject>Protein Multimerization</subject><subject>Retarding</subject><subject>Retroviridae</subject><subject>Sole</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Viruses</subject><issn>0036-8075</issn><issn>1095-9203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqN0U1Lw0AQBuBFFFurZ_GgFLx4STu7m2xnj1I_Wih4Ua9hM5lISprUbFPw3xttVPDU0xzmmYGZV4hzCSMplRl7yrkkHjlXgjHqQPQl2CiwCvSh6ANoEyBMop448X4J0PasPhY9hRoUStUXF3e85aJa5-Xb0JXD2fx1uHVEecmn4ihzheezrg7Ey8P983QWLJ4e59PbRUDaWBXIELNIhdJIMElGqCIbESHhBCOVhAmSZsoyTZxSahK2ihgRo9TJyDKFeiBudnvXdfXesN_Eq9wTF4UruWp8LNFqC1KryR4U0RplwOxBJ4hKgZUtvf5Hl1VTl-3N30oao9tHDsR4p6iuvK85i9d1vnL1Rywh_soi7rKIuyzaiatub5OsOP31P89vweUOLP2mqv_6oZUIEOpPcASMkw</recordid><startdate>20170317</startdate><enddate>20170317</enddate><creator>Haynes, Barton F.</creator><creator>Burton, Dennis R.</creator><general>American Association for the Advancement of Science</general><general>The American Association for the Advancement of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SN</scope><scope>7SP</scope><scope>7SR</scope><scope>7SS</scope><scope>7T7</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7TM</scope><scope>7U5</scope><scope>7U9</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20170317</creationdate><title>Developing an HIV vaccine</title><author>Haynes, Barton F. ; Burton, Dennis R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>AIDS Vaccines - immunology</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Clinical Trials as Topic</topic><topic>gag Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>gag Gene Products, Human Immunodeficiency Virus - immunology</topic><topic>Genomes</topic><topic>Health problems</topic><topic>HIV</topic><topic>HIV Envelope Protein gp120 - genetics</topic><topic>HIV Envelope Protein gp120 - immunology</topic><topic>HIV Infections - prevention &amp; control</topic><topic>HIV Infections - therapy</topic><topic>HIV Protease - genetics</topic><topic>HIV Protease - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunogenicity, Vaccine</topic><topic>Infections</topic><topic>Lentivirus</topic><topic>Life cycle engineering</topic><topic>Mice</topic><topic>Neutralizing</topic><topic>PERSPECTIVES</topic><topic>Protein Multimerization</topic><topic>Retarding</topic><topic>Retroviridae</topic><topic>Sole</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haynes, Barton F.</creatorcontrib><creatorcontrib>Burton, Dennis R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Ecology Abstracts</collection><collection>Electronics &amp; Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Materials Business File</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts – Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Science (American Association for the Advancement of Science)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haynes, Barton F.</au><au>Burton, Dennis R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developing an HIV vaccine</atitle><jtitle>Science (American Association for the Advancement of Science)</jtitle><addtitle>Science</addtitle><date>2017-03-17</date><risdate>2017</risdate><volume>355</volume><issue>6330</issue><spage>1129</spage><epage>1130</epage><pages>1129-1130</pages><issn>0036-8075</issn><eissn>1095-9203</eissn><abstract>In 2015, 17 million HIV-infected individuals worldwide were on antiretroviral drug therapies, which are remarkably effective in suppressing the virus. Yet, 6000 people a day became newly infected, making the quest for an effective and safe HIV vaccine a major global priority. However, developing a vaccine has been difficult for reasons related to the nature of the virus and its life cycle, including early integration into the host genome and the highly glycosylated, compact, and sequence-variable nature of the envelope (Env) "spike" that is the sole target of neutralizing antibodies (and typically associated with vaccine protection). Where are we, then, on the path to a vaccine?</abstract><cop>United States</cop><pub>American Association for the Advancement of Science</pub><pmid>28302812</pmid><doi>10.1126/science.aan0662</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0036-8075
ispartof Science (American Association for the Advancement of Science), 2017-03, Vol.355 (6330), p.1129-1130
issn 0036-8075
1095-9203
language eng
recordid cdi_proquest_miscellaneous_1893901327
source JSTOR Archival Journals and Primary Sources Collection; Science Online_科学在线; Alma/SFX Local Collection
subjects AIDS Vaccines - immunology
Animals
Antibodies
Antiretroviral agents
Antiretroviral drugs
Clinical Trials as Topic
gag Gene Products, Human Immunodeficiency Virus - genetics
gag Gene Products, Human Immunodeficiency Virus - immunology
Genomes
Health problems
HIV
HIV Envelope Protein gp120 - genetics
HIV Envelope Protein gp120 - immunology
HIV Infections - prevention & control
HIV Infections - therapy
HIV Protease - genetics
HIV Protease - immunology
Human immunodeficiency virus
Humans
Immunogenicity, Vaccine
Infections
Lentivirus
Life cycle engineering
Mice
Neutralizing
PERSPECTIVES
Protein Multimerization
Retarding
Retroviridae
Sole
T-Lymphocytes, Cytotoxic - immunology
Vaccination
Vaccines
Vaccines, Synthetic - immunology
Viruses
title Developing an HIV vaccine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A03%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developing%20an%20HIV%20vaccine&rft.jtitle=Science%20(American%20Association%20for%20the%20Advancement%20of%20Science)&rft.au=Haynes,%20Barton%20F.&rft.date=2017-03-17&rft.volume=355&rft.issue=6330&rft.spage=1129&rft.epage=1130&rft.pages=1129-1130&rft.issn=0036-8075&rft.eissn=1095-9203&rft_id=info:doi/10.1126/science.aan0662&rft_dat=%3Cjstor_proqu%3E24918004%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3692-148f52416106bfc82595cc8c87852b4b8c3ecff3cedcd6be92ce8885da159ec43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1878166300&rft_id=info:pmid/28302812&rft_jstor_id=24918004&rfr_iscdi=true